BRAF V600K (~10-20% of BRAF-mutant melanomas) shares all BRAF/MEKi approvals with V600E....
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600K-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600K |
| Disease | DIS-MELANOMA |
| ESCAT tier | IA |
| Recommended combinations | dabrafenib + trametinib, encorafenib + binimetinib, vemurafenib + cobimetinib |
| Contraindicated monotherapy | BRAFi monotherapy (vemurafenib alone) — inferior to combo |
| Evidence summary | BRAF V600K (~10-20% of BRAF-mutant melanomas) shares all BRAF/MEKi approvals with V600E. Slightly lower ORR in pooled analyses (COMBI-d/v subgroup) but PFS/OS benefit preserved. Companion-diagnostic kits (cobas, THxID) detect both V600E and V600K. |
Notes
ESCAT IA (combined V600E/K). Treat identically to V600E. V600R (very rare, <1%) also responds; V600M anecdotal.
Used By
No reverse references found in the YAML corpus.